Yazan Abou-Ismail
( out of 79 reviews )

Yazan Abou-Ismail, MD

Languages spoken: Arabic, English

Clinical Locations

Sugar House Health Center

Salt Lake City
801-581-2000
Directions

  • Yazan Abou-Ismail, MD (Mouhamed Yazan Abou-Ismail) is an Assistant Professor of Medicine at the Division of Hematology and Hematologic Malignancies. He specializes in treating non-malignant hematologic disorders, with special clinical interest in disorders of hemostasis and thrombosis, in which he has authored many peer-reviewed publications. Dr. Abou-Ismail's clinical and research interests include thrombotic microangiopathies such as thrombotic thrombocytopenic purpura, immune-mediated disorders of coagulation, as well as bleeding disorders such as von Willebrand Disease and rare blood disorders. Dr. Abou-Ismail earned his medical degree from Weill Cornell Medicine in Doha, Qatar in 2014, then completed three years of Internal Medicine residency training at Rochester General Hospital in Rochester, New York. After his residency, he completed three years of Hematology and Oncology fellowship training at Case Western Reserve University, in Cleveland, OH, where he was the recipient of the 2018 Harris Foundation Award for hematology fellows. He was awarded the Faculty Teaching Award in 2022 and appointed as Associate Program Director for the University of Utah Hematology & Oncology Fellowship Program in 2023.

    For questions regarding Dr. Abou-Ismail's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at (801) 585-6906.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    Educational Commission for Foreign Medical Graduates

    Patient Rating

    4.9 /5
    ( out of 79 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    January 04, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr. Abou-Ismail was very professional and kind. He was very knowledgeable and I felt comfortable talking to him.

    November 16, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr is very intelligent and when discussing medical issues with me, he describes it layman's terms.

    November 06, 2024
    SUGAR HOUSE HEALTH CENTER

    The staff there was amazing. The physician, while nice, clearly did not care. My past team of doctors were amazing and never made me feel like I was a burden or a waste of time. This doctor did both of those in one visit. I felt like my concerns were not listened to or treated with any sort of validity. Not only that, his only focus on what could possibly be wrong was my weight. Being overweight in his eyes was the only thing wrong with me. Overweight people couldn't possibly have any other issues not caused by being fat, right? I left that appointment beyond discouraged and hating myself. I haven't been treated so poorly by a physician in a very long time. Very disappointing coming from such a large hospital organization.

    November 01, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr listened carefully and answered all my questions. Gave me easy and clear directions to follow.

    October 29, 2024
    SUGAR HOUSE HEALTH CENTER

    Doctor Abou-Ismail is great. Very informative and cheerful. Hands down my favorite and best experience with any doctor I have ever came across.

    October 19, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Abou-Ismail truly cares about you. I feel like he treats me like a friend and a patient.

    July 22, 2024
    SUGAR HOUSE HEALTH CENTER

    Highly recommend his ability to provide care in a most meaningful way. I owe him gratitude.

    July 13, 2024
    SUGAR HOUSE HEALTH CENTER

    I appreciate the concern and knowledge that he showed.

    June 28, 2024
    SUGAR HOUSE HEALTH CENTER

    Excellent service. Very competent.

  • Yazan Abou-Ismail, MD (Mouhamed Yazan Abou-Ismail) is an Assistant Professor of Medicine at the Division of Hematology and Hematologic Malignancies. He specializes in treating non-malignant hematologic disorders, with special clinical interest in disorders of hemostasis and thrombosis, in which he has authored many peer-reviewed publications. Dr. Abou-Ismail's clinical and research interests include thrombotic microangiopathies such as thrombotic thrombocytopenic purpura, immune-mediated disorders of coagulation, as well as bleeding disorders such as von Willebrand Disease and rare blood disorders. Dr. Abou-Ismail earned his medical degree from Weill Cornell Medicine in Doha, Qatar in 2014, then completed three years of Internal Medicine residency training at Rochester General Hospital in Rochester, New York. After his residency, he completed three years of Hematology and Oncology fellowship training at Case Western Reserve University, in Cleveland, OH, where he was the recipient of the 2018 Harris Foundation Award for hematology fellows. He was awarded the Faculty Teaching Award in 2022 and appointed as Associate Program Director for the University of Utah Hematology & Oncology Fellowship Program in 2023.

    For questions regarding Dr. Abou-Ismail's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at (801) 585-6906.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Assistant Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    Educational Commission for Foreign Medical Graduates

    Education history

    Fellowship Hematology & Oncology - Case Western Reserve University Fellow
    Residency Internal Medicine - Rochester General Hospital Resident
    Professional Medical Medicine - Weill Cornell Medical College in Qatar M.D.
    Doctoral Training Premedical Program - Weill Cornell Medical College in Qatar

    Selected Publications

    Journal Article

    1. Lim MY, Abou-Ismail MY (2024). Double-heterozygous FVL/PTGM: double the trouble. Blood, 143(23), 2347-2349. (Read full article)
    2. Abou-Ismail MY, Zhang C, Presson AP, Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Kreuziger LB, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY (2024). A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura. Res Pract Thromb Haemost, 8(3), 102388. (Read full article)
    3. Abou-Ismail MY, van der Wal DE, Cheong MA, Masten A, Blount L, Brown MC (2024). Can scientific journals benefit from a social media presence? An analysis of online traffic data and author perspectives. Res Pract Thromb Haemost, 8(3), 102387. (Read full article)
    4. Abou-Ismail MY, Zhang C, Presson AP, Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY (2023). A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry. Blood Adv, 8(3), 620-623. (Read full article)
    5. Zafar A, Lim MY, Abou-Ismail MY (2023). Eculizumab in the management of drug-induced thrombotic microangiopathy: A scoping review of the literature. Thromb Res, 224, 73-79. (Read full article)
    6. Kanack AJ, Jones CG, Singh B, Leger RR, Splinter NP, Heikal NM, Pruthi RK, Chen D, George G, Abou-Ismail MY, Wool GD, Gundabolu K, Padmanabhan A (2022). Off-the-shelf Cryopreserved Platelets for the Detection of HIT and VITT Antibodies. Blood, 140(25), 2722-2729. (Read full article)
    7. Kanack A, Bayas A, George G, Abou-Ismail MY, Singh B, Kohlhagen M, Splinter N, Christ M, Naumann M, Moser KA, Smock KJ, Grazioli A, Wen R, Wang D, Murray DL, Padmanabhan A (2022). Monoclonal and Oligoclonal Anti-Platelet Factor 4 Antibodies Mediate VITT. Blood, 140(1), 73-77. (Read full article)
    8. Abou-Ismail MY, Kanack A, Splinter N, Smock KJ, Moser K, Padmanabhan A (2022). Safety of BNT162b2 mRNA Vaccine Booster in the Setting of Ad26.COV2.S-associated VITT. Blood Adv, 6, 5327-5329. (Read full article)
    9. Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L 3rd, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S (2022). Does Recipient Body Mass Index Inform Donor Selection for Allogeneic Haematopoietic Cell Transplantation? Br J Haematol, 197, 326-338. (Read full article)
    10. Kanack AJ, Singh B, George G, Gundabolu K, Koepsell SA, Abou-Ismail MY, Moser KA, Smock KJ, Green D, Major A, Chan CW, Wool GD, Reding M, Ashrani AA, Bayas A, Grill DE, Padmanabhan A (2022). Persistence of Ad26.COV2.S-associated Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) and Specific Detection of VITT Antibodies. Am J Hematol, 97, 519-526. (Read full article)
    11. Thomas VM, Abou-Ismail MY, Lim MY (2021). Off-label use of Emicizumab in Persons with Acquired Haemophilia A and von Willebrand Disease: A Scoping Review of the Literature. Haemophilia, 28(1), 4-17. (Read full article)
    12. Abou-Ismail MY, Prchal JT, Deininger MW, Parker CJ, Lim MY (2021). Anticoagulation Management Post-transjugular Intrahepatic Portosystemic Shunt in Portal Hypertension Associated with Myeloproliferative Neoplasms. Blood Coagul Fibrinolysis, 32(8), 578-583. (Read full article)
    13. Abou-Ismail MY, Ravi G, Fu P, Cao S, Vuyyala S, Caimi P, Kolk M, Ferrari N, Boughan K, Cooper B, Gallogly M, Otegbeye F, Tomlinson B, de Lima M, Metheny L (2020). History of Drug use in Allogeneic Hematopoietic Cell Transplant Recipients. Bone Marrow Transplant, 56(3), 581-585. (Read full article)
    14. Abou-Ismail MY, Rodgers GM, Bray PF, Lim MY (2021). Acquired von Willebrand Syndrome in Monoclonal Gammopathy - A Scoping Review on Hemostatic Management. Res Pract Thromb Haemost, 5(2), 356-365. (Read full article)
    15. Abou-Ismail MY, Arafah Y, Fu P, Cao S, Schmaier AH, Nayak L (2020). Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab. Front Med (Lausanne), 7, 588526. (Read full article)
    16. Abou-Ismail MY, Vuyyala S, Prunty J, Schmaier AH, Nayak L (2020). Short Term Efficacy of Recombinant Porcine Factor VIII in Patients with Factor VIII Inhibitors. Haemophilia, 26(4), 601-606. (Read full article)
    17. Abou-Ismail MY, Ogunbayo GO, Secic M, Kouides PA (2017). Outgrowing the Laboratory Diagnosis of Type 1 von Willebrand Disease: A Two Decade Study. Am J Hematol, 93(2), 232-237. (Read full article)

    Review

    1. Lim MY, Abou-Ismail MY, Branch DW (2022). Differentiating and Managing Rare Thrombotic Microangiopathies during Pregnancy and Postpartum. [Review]. Obstet Gynecol, 141(1), 85-108. (Read full article)
    2. Abou-Ismail MY, James PD, Flood VH, Connell NT (2022). Beyond the Guidelines: How we Approach Challenging Scenarios in the Diagnosis and Management of von Willebrand Disease. [Review]. J Thromb Haemost, 21(2), 204-214. (Read full article)
    3. Abou-Ismail MY, Kapoor S, Citla Sridhar D, Nayak L, Ahuja S (2022). Thrombotic Microangiopathies: An Illustrated Review. [Review]. Res Pract Thromb Haemost, 6(3), e12708. (Read full article)
    4. Abou-Ismail MY, Connell NT (2021). How to Manage Bleeding Disorders in Aging Patients Needing Surgery. [Review]. Hematology Am Soc Hematol Educ Program, 2021(1), 529-535. (Read full article)
    5. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L (2020). The Hypercoagulable State in COVID-19: Incidence, Pathophysiology, and Management. [Review]. Thromb Res, 194, 101-115. (Read full article)
    6. Abou-Ismail MY, Citla Sridhar D, Nayak L (2020). Estrogen and Thrombosis: A Bench to Bedside Review. [Review]. Thromb Res, 192, 40-51. (Read full article)
    7. Citla Sridhar D, Abou-Ismail MY, Ahuja SP (2020). Central Venous Catheter-related Thrombosis in Children and Adults. [Review]. Thromb Res, 187, 103-112. (Read full article)

    Letter

    1. Lim MY, Abou-Ismail MY (2021). Left Atrial Appendage Occlusion for Management of Atrial Fibrillation in Persons with Hemophilia. [Letter to the editor]. Thromb Res, 206, 9-13. (Read full article)
    2. Abou-Ismail MY, Moser KA, Smock KJ, Lim MY (2021). Vaccine-induced Thrombotic Thrombocytopenia following Ad26.COV2.S Vaccine in a Man Presenting as Acute Venous Thromboembolism. [Letter to the editor]. Am J Hematol, 96(9), E346-E349. (Read full article)

    Other

    1. Le T, Bushan V (2013). Acknowledged contributor in Le T, Bushan V. First Aid for the USMLE Step 1. McGraw-Hill Medical.
    2. Abou-Ismail MY (2013). Preimplantation Genetic Diagnosis: An Ethical Debate. Kira'at Volume III.
    3. Abou-Ismail A, Abou-Ismail MY (2011). Addendum to Lab 14 Chapter Applying Biolab Concepts in Medicine. 1st year Premedical Program Biology Lab Manual - BIOG 103. Revised by Ogden CB, course director (Eds.).

  • News & Podcasts

    News

    Huntsman Cancer Institute News